Lexaria Bioscience Corp
LEXXW0.010USD
+0.006+135.71%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Lexaria Bioscience Corp Company
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. It operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.
Lexaria Bioscience Corp Info
Ticker SymbolLEXXW
Company nameLexaria Bioscience Corp
IPO dateOct 28, 2009
CEOMr. Richard Christopher
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address100 - 740 Mccurdy Road
CityKELOWNA
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeV1X 2P7
Phone12507656424
Websitehttps://www.lexariabioscience.com/
Ticker SymbolLEXXW
IPO dateOct 28, 2009
CEOMr. Richard Christopher
Company Executives of Lexaria Bioscience Corp
Name
Name/Position
Position
Shareholding
Change
Mr. William Edward (Ted) Mckechnie
Mr. William Edward (Ted) Mckechnie
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Shankman, CPA
Mr. Michael (Mike) Shankman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher A. (Chris) Bunka
Mr. Christopher A. (Chris) Bunka
Chairman of the Board
Chairman of the Board
--
--
Mr. John Martin Docherty
Mr. John Martin Docherty
President, Director
President, Director
--
--
Mr. Richard Christopher
Mr. Richard Christopher
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Nicholas W. (Nick) Baxter
Mr. Nicholas W. (Nick) Baxter
Independent Director
Independent Director
--
--
Mr. Albert (Al) Reese, Jr.
Mr. Albert (Al) Reese, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. William Edward (Ted) Mckechnie
Mr. William Edward (Ted) Mckechnie
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Shankman, CPA
Mr. Michael (Mike) Shankman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Christopher A. (Chris) Bunka
Mr. Christopher A. (Chris) Bunka
Chairman of the Board
Chairman of the Board
--
--
Mr. John Martin Docherty
Mr. John Martin Docherty
President, Director
President, Director
--
--
Mr. Richard Christopher
Mr. Richard Christopher
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Nicholas W. (Nick) Baxter
Mr. Nicholas W. (Nick) Baxter
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
7
55.09K
0.00%
-82.65K
2025Q3
6
45.45K
0.00%
-302.27K
2025Q2
6
45.45K
0.00%
-303.25K
2025Q1
6
45.45K
0.00%
-303.25K
2024Q4
6
46.53K
0.00%
-325.16K
2024Q3
6
69.52K
0.00%
-368.13K
2024Q2
7
261.69K
0.00%
-208.55K
2024Q1
7
168.06K
0.00%
-301.97K
2023Q4
6
260.06K
0.00%
-217.09K
2023Q3
6
477.14K
0.00%
-35.77K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Clear Street Group Inc
100.00
0%
+100.00
--
Sep 30, 2025
Heights Capital Management, Inc.
41.25K
0%
--
--
Sep 30, 2025
UBS Financial Services, Inc.
2.42K
0%
-1.77K
-42.22%
Sep 30, 2025
Clear Street LLC
--
0%
-100.00
-100.00%
Mar 31, 2025
HRT Financial LP
11.31K
0%
+11.31K
--
Sep 30, 2025
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Lexaria Bioscience Corp?
The top five shareholders of Lexaria Bioscience Corp are:
Clear Street Group Inc holds 100.00 shares, accounting for 0.00% of the total shares.
Heights Capital Management, Inc. holds 41.25K shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 2.42K shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 0.00 shares, accounting for 0.00% of the total shares.
HRT Financial LP holds 11.31K shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 100.00 shares, accounting for 0.00% of the total shares.
Heights Capital Management, Inc. holds 41.25K shares, accounting for 0.00% of the total shares.
UBS Financial Services, Inc. holds 2.42K shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 0.00 shares, accounting for 0.00% of the total shares.
HRT Financial LP holds 11.31K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Lexaria Bioscience Corp?
The top three shareholder types of Lexaria Bioscience Corp are:
Other
Other
How many institutions hold shares of Lexaria Bioscience Corp (LEXXW)?
As of 2025Q4, 7 institutions hold shares of Lexaria Bioscience Corp, with a combined market value of approximately 55.09K, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Lexaria Bioscience Corp?
In --, the -- business generated the highest revenue for Lexaria Bioscience Corp, amounting to -- and accounting for --% of total revenue.
